Figure 2: KPT-6566 impacts on cell proliferation and viability in a PIN1-dependent manner.
From: A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
(a) Growth curves of WT (left) or Pin1 KO (right) MEFs treated with the indicated concentrations of KPT-6566 or DMSO. (b) Immunoblotting of the indicated cell cycle-related proteins in WT or Pin1 KO MEFs treated with 5 μM KPT-6566 (+) or DMSO (−) for 48 h. (c) Growth curves in empty-vector transduced Pin1 KO MEFs (Vector, left) or Pin1 KO MEFs reconstituted with HA-PIN1 (PIN1, right) treated with KPT-6566 or DMSO. (d) Immunoblotting of the indicated proteins in Pin1 KO MEFs or Pin1 KO MEFs reconstituted with HA-PIN1 treated with 5 μM KPT-6566 (+) or DMSO (−) for 48 h. (e) Left, immunoblotting of the indicated proteins in cell lysates from MCF10A and MCF10AT1 cells. Right, cell viability (WST) assay of MCF10A and MCF10AT1 treated with the indicated concentrations of KPT-6566 for 48 h. (f) Immunoblotting of PIN1 in normal breast epithelial cells (MCF10A, HMEC) and in the indicated cancer cell lines. (g) Cell viability (ATPlite) assay of the same cell lines as in (f) treated with the indicated concentrations of KPT-6566 for 48 h. b,d–f Actin levels are reported as loading control; size markers are indicated. Data shown in a,c,e,g are the means±s.d. of n=3 independent experiments, **P<0.01, n.s. not significant; two-tailed Student’s t-test.
